On Tuesday, December 15, from 11 am to noon EST, The American Journal of Managed Care will host a tweetchat with Leah Binder, MA, MGA, president and CEO of The Leapfrog Group, about hospital quality ratings, patient safety, and healthcare outcomes.
PLAINSBORO, N.J.— In the most recent Hospital Safety Score report, The Leapfrog Group found a number of positive trends for certain hospital-acquired conditions and safety measures, but noted that areas for improvement remain.
On Tuesday, December 15, from 11 am to noon EST, The American Journal of Managed Care (AJMC) will host a tweetchat with Leah Binder, MA, MGA, president and CEO of The Leapfrog Group, about hospital quality ratings, patient safety, and healthcare outcomes.
Binder, who was the keynote speaker at AJMC’s ACO and Emerging Healthcare Delivery Coalition fall live meeting in October, will answer questions from participants and discuss topics that include the relevancy of individual hospital quality ratings, how the use of health technology has affected patient safety, and how consumers view quality ratings.
“Although progress has been made, we still need more transparency and accountability in our health care system,” said Binder. “I’m honored to partner with AJMC to have an open conversation with hospitals and purchasers on ways to improve quality, patient safety and transparency for consumers.”
AJMC and The Leapfrog Group encourage Twitter users to submit questions and participate in the chat on Tuesday, December 15, by using #AJMCchat. And don’t forget to follow @AJMC_Journal, @LeahBinder, and @LeapfrogGroup.
In March 2015, Binder wrote a commentary for AJMC’s sister publication, The American Journal of Accountable Care, highlighting the expanding surge of consumerism in healthcare.
About the Journals
The American Journal of Managed Care celebrates its 20th year in 2015 as the leading peer-reviewed journal dedicated to issues in managed care. Other titles in the franchise include The American Journal of Pharmacy Benefits, which provides pharmacy and formulary decision-makers with information to improve the efficiency and health outcomes in managing pharmaceutical care, and The American Journal of Accountable Care, which publishes research and commentary on innovative healthcare delivery models facilitated by the 2010 Affordable Care Act. AJMC’s Evidence-Based series brings together stakeholder views from payers, providers, policymakers and pharmaceutical leaders in oncology and diabetes management. To order reprints of articles appearing in AJMC publications, please call (609) 716-7777, x 131.
About The Leapfrog Group
Founded in 2000 by large employers and other purchasers, The Leapfrog Group is a national nonprofit organization driving a movement for giant leaps forward in the quality and safety of American health care. The flagship Leapfrog Hospital Survey collects and transparently reports hospital performance, empowering purchasers to find the highest-value care and giving consumers the lifesaving information they need to make informed decisions. Hospital Safety Score, Leapfrog’s other main initiative, assigns letter grades to hospitals based on their record of patient safety, helping consumers protect themselves and their families from errors, injuries, accidents, and infections.
Nicole Beagin (609) 716-7777 x 131
CONTACT:
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More